Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer

被引：0
|
作者：
Seruga, B. [1 ]
Gan, H. K. [1 ]
Knox, J. J. [1 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Div Hematol & Med Oncol, Toronto, ON, Canada
来源：
CURRENT ONCOLOGY | 2009年 / 16卷
关键词：
Sunitinib; sorafenib; temsirolimus; toxicity; side effects; management; RENAL-CELL CARCINOMA; TYROSINE KINASE INHIBITOR; CARDIAC-HYPERTROPHY; INTERFERON-ALPHA; DOUBLE-BLIND; SUNITINIB; HYPOTHYROIDISM; HYPERTENSION; MANAGEMENT; SAFETY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The toxicities of new, targeted drugs may diminish their effectiveness in advanced kidney cancer if those toxicities are not recognized and properly addressed early in patient treatment. Most of the drug-related toxicities in advanced kidney cancer are manageable with supportive care, obviating a need for long interruptions, dose reductions, or permanent discontinuation of the treatment.
引用
收藏
页码：S54 / S61
页数：8
相关论文
共 50 条
  • [21] Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer
    Takami, Hiroshi E.
    ENDOCRINE JOURNAL, 2011, 58 (03) : 151 - 153
  • [22] Synchronous Chemoradiation and Multiple Targeted Drugs for Advanced Head and Neck Cancer
    Brizel, D. M.
    Yoo, D. S.
    Ready, N.
    Kirkpatrick, J. P.
    Dewhirst, M. W.
    Scher, R. L.
    Cleland, E.
    MacFall, J.
    Barboriak, D.
    Craciunescu, O.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S175 - S176
  • [23] New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management
    Frank Kroschinsky
    Friedrich Stölzel
    Simone von Bonin
    Gernot Beutel
    Matthias Kochanek
    Michael Kiehl
    Peter Schellongowski
    Critical Care, 21
  • [24] New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management
    Kroschinsky, Frank
    Stoelzel, Friedrich
    von Bonin, Simone
    Beutel, Gernot
    Kochanek, Matthias
    Kiehl, Michael
    Schellongowski, Peter
    CRITICAL CARE, 2017, 21
  • [25] Preventative measures and prompt recognition are vital when managing dermatological toxicities associated with targeted cancer therapies
    Drugs & Therapy Perspectives, 2015, 31 (4) : 128 - 132
  • [26] Survival outcomes for advanced kidney cancer patients in the era of targeted therapies
    Rao, Arpit
    Wiggins, Charles
    Lauer, Richard C.
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (09)
  • [27] Circulating levels of ligand as a potential biomarker for optimal dosing of targeted antibody drugs to the epidermal growth factor receptor
    Mutsaers, A. J.
    Ebos, J. M.
    Lee, C.
    Francia, G.
    Man, S.
    Hicklin, D. J.
    Iznaga-Escobar, N.
    Kerbel, R. S.
    EJC SUPPLEMENTS, 2006, 4 (12): : 67 - 68
  • [28] Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
    Patel, Priti
    Srinivas, Sandy
    CURRENT CLINICAL PHARMACOLOGY, 2011, 6 (03): : 181 - 188
  • [29] Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers
    Liu, Sariah
    Nikanjam, Mina
    Kurzrock, Razelle
    ONCOTARGET, 2016, 7 (10) : 11310 - 11320
  • [30] Optimal strategy in managing advanced melanoma
    Uchi, Hiroshi
    JOURNAL OF DERMATOLOGY, 2024, 51 (03): : 324 - 334
12345